Results of a phase 2 trial of the Novavax reconstituted SARS-CoV-2 nanoparticle vaccine
Novavax, Inc., the American vaccine development company, has been developing a COVID-19 nanoparticle protein recycling vaccine called NVX-CoV2373. The full-length spike protein of respiratory respi…
-2.jpg)